Insmed Inc Reports Strong Q1 2025 Financial Results and Business Update
BRIDGEWATER, N.J., May 8, 2025 /PRNewswire/ – Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on serving patients with serious and rare diseases, today announced its financial results for the first quarter ended March 31, 2025, alongside a comprehensive business update. The company, based in Bridgewater, United States, and trading on the Nasdaq stock exchange, reported a total revenue of $92.8 million for the first quarter of 2025. This figure represents a 23% growth over the same period in 2024, underscoring the company’s robust performance in its commercial operations.
Key Highlights from the First Quarter:
ARIKAYCE® Revenue Growth: The company’s flagship product, ARIKAYCE® (amikacin liposome inhalation suspension), contributed significantly to the revenue, with total sales reaching $92.8 million. This growth is part of Insmed’s broader strategy to expand its market presence and deliver impactful therapies to patients.
Brensocatib Development Progress: Insmed’s New Drug Application (NDA) for Brensocatib, aimed at treating patients with bronchiectasis, remains on track. The Prescription Drug User Fee Act (PDUFA) target action date is set for August 12, 2025. Additionally, the company has completed enrollment for the Phase 2b BiRCh study of Brensocatib in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSsNP), with topline data anticipated by the end of 2025.
TPIP Phase 2 Study Completion: The Phase 2b study of TPIP in patients with Pulmonary Arterial Hypertension (PAH) has been completed, with topline data expected in June 2025. This milestone is part of Insmed’s commitment to advancing its clinical pipeline.
MAA Filings Accepted: The Marketing Authorization Application (MAA) filings for Brensocatib in patients with bronchiectasis have been accepted by both the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), marking a significant step forward in the drug’s regulatory journey.
Revenue Guidance for 2025: Insmed has reiterated its global ARIKAYCE revenue guidance range for 2025, projecting $405 million to $425 million. This forecast reflects double-digit growth compared to 2024, highlighting the company’s confidence in its commercial strategy and product pipeline.
Analyst Expectations:
According to a report by finanzen.net, 16 analysts expect an average earnings per share (EPS) of -$1.336 for the first quarter, indicating a loss of 26.04% compared to the previous year’s EPS of -$1.060. Despite the anticipated loss, analysts project a 22% increase in revenue to $92.1 million from $75.5 million in the same quarter of the previous year. For the full fiscal year 2025, 17 analysts predict an EPS of -$5.229, a slight improvement from the previous year’s -$5.570. Revenue expectations for the year stand at $468.8 million, up from $363.7 million in 2024.
Insmed’s first-quarter results and business update reflect the company’s strategic focus on growth and innovation in the biopharmaceutical sector. With several critical milestones on the horizon, Insmed continues to demonstrate its commitment to transforming the lives of patients with serious and rare diseases.